

Special Issue

Inequality in Immunization 2024

Message from the Guest Editors

Inequalities persist in the coverage of immunization globally and across the life course. Evidence has revealed gaps or gradients in childhood and adult immunization within and across countries, and with respect to dimensions of inequality such as sex, gender, socio-economic status, place of residence and more. Yet, our understandings of patterns of inequalities in immunization remain incomplete. The year 2024 marks 50 years of the Expanded Programme on Immunization (EPI). The EPI has galvanized national and global collaboration and helped set up essential infrastructure and standardized processes to universalize access to immunization. In this Special Issue, we place emphasis on research and review articles that deepen our understanding of immunization inequalities as well as highlight entry points or modalities to reduce them. We encourage submissions that apply rigorous and innovative methodological approaches, including multilevel modeling, compound and/or intersectional vulnerabilities or disadvantages, and geospatial approaches, as well as statistical and computational innovations in understanding and summarizing inequalities in immunization.

Guest Editors

Dr. Ahmad Reza Hosseinpoor
Dr. Devaki Nambiar
Dr. Nicole Bergen
Dr. M. Carolina Danovaro
Dr. Hope L. Johnson
Dr. Ciara Sugerman

Deadline for manuscript submissions

closed (15 June 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/182837

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

